ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
ANAVEX2-73-RS-003 is a Phase 2/3, double-blind, randomized, placebo-controlled dose
escalation safety, tolerability and efficacy study in patients 5-17 years of age with RTT
using endpoints including multiple clinical and exploratory molecular and biochemical
measures.